RxDoctor Payments Data

Cara Cook

Nurse Practitioner · Texarkana, TXNPI 1679556336

Payments from drug & device makers

$7,356in general payments, 2019–2025

Across 542 payments — averaging $13.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Abbott$1K
  • Lilly USA, LLC$764
  • Novo Nordisk$417
  • Pfizer$332
  • GSK$286
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$7,30199%
  • Education$370%
  • Other$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,356 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$128,120
Medicare patients
365
Services billed
4,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide159$155,264
EliquisApixaban111$81,342
MounjaroTirzepatide71$76,776
FarxigaDapagliflozin Propanediol43$40,557
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog36$26,749
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$26,078
ProliaDenosumab13$22,301
RybelsusSemaglutide17$18,324
Tresiba Flextouch U-100Insulin Degludec14$17,860
LinzessLinaclotide19$17,681
Soliqua 100-33Insulin Glargine/Lixisenatide19$16,303
Repatha SyringeEvolocumab16$14,658
TrintellixVortioxetine Hydrobromide22$14,171
TrulicityDulaglutide14$12,847
Tresiba Flextouch U-200Insulin Degludec13$10,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$417$173,588176 claims
Lilly USA, LLCMounjaro, Trulicity$764$89,62385 claims
PfizerEliquis$332$81,342111 claims
AstraZenecaFarxiga$81$40,55743 claims
GSKTrelegy Ellipta$286$26,07836 claims
AmgenProlia$181$22,30113 claims
AbbVieLinzess, Synthroid$1,294$21,60071 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$89$16,30319 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$252$14,17122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Texarkana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →